Yoh found that expression of the ABCG2, but not of Pgp, MRP1, MRP2, and MRP3, was a predictive factor of poor clinical outcome in advanced NSCLC patients even though the role of ABCG2 as transporter of platinum conjugates is still controversial [12]. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.